What is the 13F Pro Quality Score for ISRG?

13F Pro ranks INTUITIVE SURGICAL INC (ISRG) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View ISRG's current score at https://13fpro.ai/company/ISRG (free sign-up required for the full ranking).

Which hedge funds own the most ISRG stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of ISRG include BlackRock,, VANGUARD CAPITAL MANAGEMENT, STATE STREET. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/ISRG as soon as new 13F filings post.

Where does 13F Pro source ISRG data?

All INTUITIVE SURGICAL INC fundamentals and ownership data come directly from SEC EDGAR. INTUITIVE SURGICAL INC files with the SEC under CIK 1035267. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is ISRG in?

INTUITIVE SURGICAL INC (ISRG) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

What drives ISRG's revenue?

Per INTUITIVE SURGICAL INC's latest 10-Q filed with the SEC on 2026-07-21, the biggest revenue drivers are: Instruments and accessories ($1.73B, +18% YoY); Systems ($685M, +19% YoY); Service ($472.4M, +21% YoY). Figures are extracted from the filing text and machine-verified against the document. Full breakdown at https://13fpro.ai/company/ISRG.

What are ISRG's largest expenses?

INTUITIVE SURGICAL INC's latest 10-Q reports these as the largest expense items: Total cost of revenue ($931.9M, vs $822.1M prior year); Selling, general, and administrative ($617.9M, +10% YoY); Research and development ($370.6M, +18% YoY). Sourced directly from SEC EDGAR filing text for Q2 FY2026 (quarter ended June 30, 2026).

How often is ISRG research updated on 13F Pro?

ISRG's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

INTUITIVE SURGICAL INC(ISRG)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqlarge

Institutional-grade research for retail investors

SEC EDGAR: CIK 1035267 ISRG stock profile & AI dashboard →

13F Pro Quality Score

79.9/100

Rank #30 of 2,961 stocksTOP 5%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

82.0/100

Profitability

87.1/100

Balance Sheet

93.1/100

Earnings Quality

65.2/100

Free Cash Flow

83.3/100

Institutional Flow

81.7/100

Revenue Scale

87.3/100

Dilution Risk

19.2/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why ISRG Scores 80/100

exact factor attribution · 2026-09-11

ISRG's composite is driven by revenue growth and scale, held back by shareholder dilution. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Revenue growth

+6.4 pts

82th pct

Scale

+5.6 pts

87th pct

Profitability

+5.6 pts

87th pct

Free cash flow

+5.0 pts

83th pct

Capital efficiency

+4.3 pts

93th pct

Institutional flow

+1.6 pts

82th pct

Earnings quality

+1.5 pts

65th pct

Earnings growth

+1.4 pts

79th pct

Shareholder dilution

-1.5 pts

19th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

ISRG Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for INTUITIVE SURGICAL INC (ISRG), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ISRG at 79.9/100 on a 32-signal composite quality model, placing it at rank #30 of 2,961 stocks — the top 5% of the AI-ranked universe. ISRG scores in the top quartile across balance sheet strength (93.1), revenue scale (87.3), profitability (87.1). Shareholder dilution risk is elevated at 19.2/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), INTUITIVE SURGICAL INC reports quarterly revenue of $2.9B, net income of $818.1M, an operating margin of 33.6%. Top institutional holders of ISRG by reported 13-F value include BlackRock, VANGUARD CAPITAL MANAGEMENT, STATE STREET, based on the most recent SEC filings. ISRG trades on the Nasdaq exchange and files with the SEC under CIK 1035267. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ISRG daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for INTUITIVE SURGICAL INC directly from SEC EDGAR. INTUITIVE SURGICAL INC's 13F Pro composite quality score has ranged between 67 and 82 since 2021, currently 79.9 — an improving long-term trajectory across 68 quarterly and live scoring snapshots.

✦

Fun facts about INTUITIVE SURGICAL INC

Quirks, history, and lore behind ISRG — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. medical device company · large-cap · listed on Nasdaq · headquartered in California.
2
The Numbers
Annual revenue of roughly $7–8 billion, with operating margins that make most of healthcare jealous — north of 25%. Selling hardware is just the beginning; the real money is in consumables and service contracts.
3
The History
Founded in the late 1990s, it commercialized technology that traces back to DARPA-funded research aimed at letting surgeons operate on wounded soldiers from a distance.
4
The Secret
Its business model is essentially razor-and-blades: place the machine in a hospital, then charge for every single-use instrument and accessory used in every procedure — for life.
5
The Lore
Its flagship system has performed millions of minimally invasive surgeries worldwide and is named after a Renaissance genius — because apparently a robot that outsmarts your surgeon needed a suitably intimidating brand name.
6
The Giveaway
If your doctor said your prostatectomy or hysterectomy would be done by four robotic arms controlled from a console across the room, you were almost certainly meeting the da Vinci Surgical System.

▶ Think you know your stocks? Play the Daily Ticker

What's Driving ISRG's Business? Latest 10-Q Breakdown

✓ 33/33 datapoints verified

AI-extracted from INTUITIVE SURGICAL INC's 10-Q filed 2026-07-21 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Q2 revenue rose 19% to $2.89B as da Vinci procedures grew 15% and 468 systems were placed, lifting gross margin to 67.8%.

Biggest Revenue Drivers

Instruments and accessories$1.73B+18% YoY

Driven by ~15% higher da Vinci procedure volume, ~36% higher Ion procedure volume, and higher revenue per procedure from da Vinci 5 and SP mix

Systems$685M+19% YoY

Primarily driven by an increase in da Vinci system placements, partially offset by a higher proportion of placements under operating leases

Biggest Revenue Drivers

Total revenue: $2.89B+19% YoY

Instruments and accessories$1.73B+18% YoY

Driven by ~15% higher da Vinci procedure volume, ~36% higher Ion procedure volume, and higher revenue per procedure from da Vinci 5 and SP mix

Within Instruments and accessories

U.S. instruments and accessories$1,180.4M

OUS instruments and accessories$554.5M

Systems$685M+19% YoY

Primarily driven by an increase in da Vinci system placements, partially offset by a higher proportion of placements under operating leases

Service$472.4M+21% YoY

Larger installed base of systems producing service revenue and favorable product mix, including from da Vinci 5 placements

Largest Expense Items

Total cost of revenue$931.9Mvs $822.1M prior year

Included $20.8M of tariffs and other trade measures, offset by $35.9M of IEEPA tariff refunds from prior periods

Selling, general, and administrative$617.9M+10% YoY

Higher personnel-related expenses from increased headcount and compensation, plus higher infrastructure costs including depreciation

Research and development$370.6M+18% YoY

Higher direct project costs supporting an expanded portfolio of product development initiatives and higher headcount

Income tax expense$231.4M+38% YoY

Effective rate rose to 21.9% from 20.2% on lower excess tax benefits from employee equity plans

Margins: Gross margin rose to 67.8% from 66.3%. Product margin gained on IEEPA tariff refunds, lower logistics costs, and fixed overhead leverage, partly offset by higher intangible amortization.

Watch Items from the Filing

China placements fell short of expectations on domestic competition and the government governance campaign; NHSA issued a national robotic-surgery pricing framework provinces must implement.
Tariffs and trade measures added $20.8M to cost of revenue in the quarter ($48.8M year-to-date); a significant majority of instruments are made in Mexico and most endoscopes in Germany.
Operating lease placements were 54% of da Vinci placements versus 49% a year ago, deferring systems revenue; usage-based leases have no minimum payments.
Certified antitrust class action over EndoWrist service and repair is set for trial September 14, 2027; the Company cannot estimate a loss or range.
U.S. da Vinci procedure growth decelerated to 12% from 14%, with bariatric procedures down high-single digits and ACA subsidy expiration cited as a modest drag.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →Share on X

Revenue

Q2 2026

$2.9B

Net Income

Q2 2026

$818.1M

Free Cash Flow

Q2 2026

$948.4M

Operating Margin

Q2 2026

33.6%

ROIC

Q2 2026

21.4%

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+20.5% YoY

$10.06BFY 2025

FY22 $6.22BFY23 $7.12BFY24 $8.35BFY25 $10.06B

Net Income

+23.0% YoY

$2.86BFY 2025

FY22 $1.32BFY23 $1.80BFY24 $2.32BFY25 $2.86B

Operating Income

+25.4% YoY

$2.95BFY 2025

FY22 $1.58BFY23 $1.77BFY24 $2.35BFY25 $2.95B

EPS (Diluted)

+22.6% YoY

$7.87FY 2025

FY22 $3.65FY23 $5.03FY24 $6.42FY25 $7.87

Total Assets

+9.2% YoY

$20.46BFY 2025

FY22 $12.97BFY23 $15.44BFY24 $18.74BFY25 $20.46B

Op. Cash Flow

+25.5% YoY

$3.03BFY 2025

FY22 $1.49BFY23 $1.81BFY24 $2.42BFY25 $3.03B

Free Cash Flow

+91.0% YoY

$2.49BFY 2025

FY22 $958.4MFY23 $749.6MFY24 $1.30BFY25 $2.49B

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$10.06B +20.5%	$8.35B +17.2%	$7.12B +14.5%	$6.22B +9.0%	$5.71B +31.0%	$4.36B
Net Income	$2.86B +23.0%	$2.32B +29.2%	$1.80B +36.0%	$1.32B -22.4%	$1.70B +60.7%	$1.06B
Operating Income	$2.95B +25.4%	$2.35B +32.9%	$1.77B +12.0%	$1.58B -13.4%	$1.82B +73.5%	$1.05B
EPS (Diluted)	$7.87 +22.6%	$6.42 +27.6%	$5.03 +37.8%	$3.65 -21.7%	$4.66 +375.5%	$0.98
Total Assets	$20.46B +9.2%	$18.74B +21.4%	$15.44B +19.0%	$12.97B -4.3%	$13.55B +21.4%	$11.17B
Operating Cash Flow	$3.03B +25.5%	$2.42B +33.1%	$1.81B +21.7%	$1.49B -28.6%	$2.09B +40.7%	$1.48B
Free Cash Flow	$2.49B +91.0%	$1.30B +73.9%	$749.6M -21.8%	$958.4M -45.2%	$1.75B +53.1%	$1.14B

Get alerted when ISRG's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for INTUITIVE SURGICAL INC including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of ISRG

BlackRock, Inc.
$11.9B30,024,648 sh
VANGUARD CAPITAL MANAGEMENT LLC
$9.2B23,131,099 sh
STATE STREET CORP
$6.4B16,063,040 sh
Invesco Ltd.
$4.7B11,843,563 sh
PRICE T ROWE ASSOCIATES INC /MD/
$4.5B11,256,570 sh
GEODE CAPITAL MANAGEMENT, LLC
$3.4B8,534,767 sh
Capital World Investors
$3.1B7,742,681 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$2.9B7,243,264 sh
MORGAN STANLEY
$2.6B6,561,322 sh
NORGES BANK
$2.0B4,954,874 sh

Fund	Value	Shares
BlackRock, Inc.	$11.9B	30,024,648
VANGUARD CAPITAL MANAGEMENT LLC	$9.2B	23,131,099
STATE STREET CORP	$6.4B	16,063,040
Invesco Ltd.	$4.7B	11,843,563
PRICE T ROWE ASSOCIATES INC /MD/	$4.5B	11,256,570
GEODE CAPITAL MANAGEMENT, LLC	$3.4B	8,534,767
Capital World Investors	$3.1B	7,742,681
VANGUARD PORTFOLIO MANAGEMENT LLC	$2.9B	7,243,264
MORGAN STANLEY	$2.6B	6,561,322
NORGES BANK	$2.0B	4,954,874

Companies Similar to ISRG

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

VRTX

VERTEX PHARMACEUTICALS INC / MA

AI score

Very similar · 41 shared holders

Capital World Investors JENNISON ASSOCIATES LLC LOOMIS SAYLES & CO L P

LLY

ELI LILLY & Co

AI score

Very similar · 48 shared holders

Capital World Investors JENNISON ASSOCIATES LLC Capital Research Global Investors

SYK

STRYKER CORP

AI score

Very similar · 36 shared holders

Capital Research Global Investors Clearbridge Investments, LLC National Pension Service

IDXX

IDEXX LABORATORIES INC /DE

AI score

Very similar · 36 shared holders

Capital Research Global Investors Alyeska Investment Group, L.P.Clearbridge Investments, LLC

AMGN

AMGEN INC

AI score

Very similar · 34 shared holders

Capital World Investors Capital Research Global Investors National Pension Service

BSX

BOSTON SCIENTIFIC CORP

AI score

Very similar · 45 shared holders

Capital World Investors Capital Research Global Investors Clearbridge Investments, LLC

ABBV

AbbVie Inc.

AI score

Very similar · 42 shared holders

Capital World Investors Capital Research Global Investors FAYEZ SAROFIM & CO

RMD

RESMED INC

AI score

Very similar · 23 shared holders

Swedbank AB Employees Provident Fund Board WORLDQUANT MILLENNIUM ADVISORS LLC

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put ISRG on your watchlist

Track score changes the day INTUITIVE SURGICAL INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is ISRG a good stock to buy?

13F Pro's AI-powered analysis of INTUITIVE SURGICAL INC (ISRG) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ISRG are available on the ISRG stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. ISRG is classified as a large company.

Which hedge funds own ISRG?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ISRG. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of INTUITIVE SURGICAL INC's investment landscape.